A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
Komal JhaveriDejan JuricYoon Sim YapSara CrestaRachel M LaymanFran Ois P DuhouxCatherine TerretShunji TakahashiJens HuoberNicole KundamalQing ShengAlejandro BalbinYan JiWei HeAdam CrystalSerena De VitaCurigliano GiuseppePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
LSZ102 was well tolerated alone and with ribociclib and had a manageable safety profile with alpelisib. Preliminary clinical activity was observed in combination use.
Keyphrases